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Abstract
Background: It has been suggested that the initial differentiation of endothelial and hematopoietic cells during embryogenesis
occurs from a common progenitor, called hemangioblast (hB). We hypothesized that these cells with dual hematopoietic/
endothelial potential could be used in future regenerative medicine.
Methods: We used the two-step differentiation technology to generate bipotential blast cells from human embryonic stem cells
(hES). This involved short differentiation in our in vitro EB system followed by differentiation in semisolid culture medium
supplemented with mixture of cytokines.
Results: The occurrence of blast-colony-forming cells (BL-CFC) during EB differentiation (day 0–6) was transient and peaked
on day 3. The emergence of this event was associated with expression of mesoderm gene T, and inversely correlated with
expression of endoderm gene FoxA2. Similarly, the highest BL-CFC number was associated with increase in expression of early
hematopoietic/endothelial genes: CD34, CD31 and KDR. The derived colonies were composed of 30–50 blast cells on day 6 in
culture. These cells had homogenous appearance in Wright-Giemsa stain, but to a different extent expressed markers of
immature hematopoietic and endothelial cells (CD31, CD34, VE-cadherin, Flt-1) and mature differentiated cells (CD45, CD33,
CD146). We found that some of them expressed fetal and embryonic globin genes. Interestingly, these cells expressed also HLA
class I molecules, however at very low levels compared to endothelial and hematopoietic cells. The blast cells could be
successfully differentiated to hematopoietic cells in a CFU assay. In these conditions, blast cells formed CFU-M colonies (63.4 ±
0.8%) containing macrophages, BFU-E colonies (19.5 ± 3.5%) containing nucleated red blood cells, and CFU-EM colonies (17.1
± 2.7%) composed of macrophages and nucleated erythrocytes. Cells of CFU-EM and BFU-E colonies expressed both ε – and
γ- globin genes, but not adult-type γ-globin. When in endothelial cell culture conditions, blast cells differentiated to endothelial
cells which had the ability to take up Dil-Ac-LDL and to form complex vascular networks in Matrigel.
Conclusion: 1) Hematoendothelial precursors exist transiently in early embryonic development and form single cell-derived
colonies; 2) their differentiation can be tracked by the use of chosen molecular markers; 3) blast colonies consist of cells having
properties of endothelial and hematopoietic precursors, however the issue of their ability to maintain dual properties over time
needs to be further explored; 4) blast cells can potentially be used in regenerative medicine due to their low expression of HLA
molecules.
Published: 22 April 2009
Journal of Translational Medicine 2009, 7:27 doi:10.1186/1479-5876-7-27
Received: 3 December 2008
Accepted: 22 April 2009
This article is available from: http://www.translational-medicine.com/content/7/1/27
© 2009 Basak et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Translational Medicine 2009, 7:27 http://www.translational-medicine.com/content/7/1/27
Page 2 of 10
(page number not for citation purposes)
Introduction
The first hematopoietic and vascular cells develop from
extra-embryonic mesoderm in the murine yolk sac at day
7.5 of gestation [1,2]. Once formed, these early progeni-
tors organize into blood islands that consist of primitive
erythroblasts surrounded by a layer of endothelial cells
[3]. Close association of these two lineages led us to the
hypothesis that they must arise from a common endothe-
lio-hematopoietic precursor called hemangioblast [4-6].
During embryonic life, next waves of hematopoiesis occur
in the aorta-gonad-mesonephros region (AGM), fetal
liver, and finally in the bone marrow. However, the possi-
bility of primitive hematopoiesis in other embryonic sites
has been suspected for a long time. Sequeira Lopez et al.
demonstrated that multiple regions within the embryo are
capable of forming blood before and during organogene-
sis [7]. Therefore, there seems to be a widespread occur-
rence of hemo-vasculogenesis, the formation of blood
vessels accompanied by the simultaneous generation of
red blood cells [1,7-9]. When a vascular lumen forms, the
erythroblasts "bud" from endothelial cells into the form-
ing vessel [7,8]. Understanding the intrinsic ability of tis-
sues to manufacture their own blood cells and vessels has
the potential to advance the field of organogenesis, regen-
eration medicine and tissue engineering [10].
Subsequently, several investigators have identified human
embryonic stem (hES) cell-derived populations that dis-
play both hematopoietic and endothelial potential [11-
14]. Hemangioblast was identified as the cell which gave
rise to colonies of blast-like cells (BLCs) [12]. These BLCs
expressed KDR and represented a transient population
that preceded development of primitive erythroid lineage.
Similarly, progenitor comparable to the BLCs has been
identified in the early gastrulating mouse embryo [15].
Mapping studies revealed that the embryo hemangiob-
lasts exist in highest numbers in the posterior region of
the primitive streak. This observation further supported
the notion that hematopoietic commitment is initiated
prior to the formation of yolk sac and blood islands.
It is well known how the immune system responds to con-
ventional cell, tissue and organ transplants. However, the
immune response to ES cell-derived grafts is difficult to
predict due to the lack of donor-type vasculature,
endothelial cells and professional antigen-presenting cells
(APCs) in cellular transplants. The specific rejection of
transplanted organs and tissues is primarily mediated by
T cells and occurs mostly because of allelic differences
between graft and recipient at their polymorphic major
histocompatibility complex (MHC) molecules called
human leukocyte antigen (HLA) in humans. Two types of
MHC molecules exist, class I and II, and their function is
to present antigenic peptides to CD8+ and CD4+ T cells,
respectively. While the MHC class II antigens are normally
present only on macrophages, dendritic cells, B cells and
thymic epithelial cells, the MHC class I molecules are con-
stitutively expressed at various levels on the surface of all
adult nucleated cells [16]. Up to 1% of peripheral T cells
in each individual can cross-react with allogeneic MHC
antigens on transplanted cells [17], and that is why T cell-
mediated allorejection is a rapid and vigorous process,
which is mostly supported by preexisting memory T cells
that have less stringent requirements for activation. Data
on immunological properties of human and murine ES
cells and their differentiated derivatives are controversial,
ranging from those claiming unique immune-privileged
properties for ES cells to those, which contradict these
conclusions. This indicates that much more research is
required to definitively understand the immunological
features of ES cell derived progenitors. In this study, we
examined the expression profile of HLA molecules on the
surface of human ES cells, EB cells and blast-like cells. We
demonstrated extremely low levels of HLA-A2 expression
in the undifferentiated H9 human ES cell line, somewhat
elevated HLA expression on the EB cells, and a moderately
elevated HLA expression on the surface of combined blast
colonies cells, as well as on cells derived from individual
blast colonies. Therefore, this study represents an impor-
tant attempt to define the HLA antigen expression and the
graft rejection issue of human ES cells and their progeni-
tors at different levels of differentiation.
In context of the increasing focus on regenerative medi-
cine and the potential for development of stem cell based
therapies for human diseases, the characterization and
functional analysis of early mesodermal cell populations
and their immediate progeny-hemangioblast-is of partic-
ular interest [18]. Therefore, we hypothesized that dual
endothelio-hematopoietic progenitor can be obtained
from hES cell-derived mesodermal progenitors early in
the embryonal development. We expected that these blast
cells would be able to form colonies of functional cells
with dual hematopoietic/endothelial potential. Low
expression of MHC class I molecules would allow their
engraftment against histocompatibility barriers, and thus
future clinical applications.
Methods
hES cell culture and differentiation
The hES cell line H9 (registered as WA09 by the US
National Institutes of Health) was purchased from WiCell
Research Institute (WI, USA). Cells have been cultured on
the feeder layer of mouse embryonic fibroblasts (MEFs,
Global Stem Cell Technologies, USA) in the culture
medium consisting of DMEM-F12 with Knockout Serum
Replacement (20%), L-Glutamine (0.8 mM), 2-Mercap-
toethanol (119 μM), Non-Essential Amino Acid Solution
(1%), and human recombinant bFGF (10 ng/ml) (all
from Invitrogen, CA, USA) in standard cell culture condi-Journal of Translational Medicine 2009, 7:27 http://www.translational-medicine.com/content/7/1/27
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tion (37°C, 5% CO2) and split mechanically every 3rd
day. When the hES culture reached 75% confluence, cells
were used for differentiation studies in embryoid body
(EB) system. The hES cells have been detached mechani-
cally and small clumps of cells were resuspended in
serum-free Stemline II Hematopoietic Stem Cell Expan-
sion Medium (Sigma) containing BMP-4 and VEGF (50
ng/ml of each) (Invitrogen, CA, US). After 48 hours of
incubation, half of the culture media was replaced with
the Stemline II media containing BMP-4 and VEGF (both
at 50 ng/ml), SCF, Tpo, and FLT3 ligand (all at 40 ng/ml)
(Invitrogen, CA, US). When EB culture was performed for
longer than 3 days, half of the medium was replaced every
48 hours with fresh medium containing BMP-4, VEGF,
SCF, Tpo, and FLT3 ligand at concentrations described
above. In the majority of experiments, EBs were collected
after 72 hours of culture and dispersed to single cell sus-
pension by incubation with Trypsin (0.05%) and EDTA
(Invitrogen), and passing through 22 G needle and 40 μm
cell strainer. Single cells were resuspended in Stemline II
medium at a concentration of 2–5 × 106 cells/ml and fur-
ther diluted in Methocult SF H4436 semisolid medium
(Stemcell Technologies, Canada) at ratio of 1:30. The
above culture medium was supplemented with BMP-4,
VEGF, Tpo, and FLT3 ligand (all at 50 ng/ml) and cultured
in Low Attachment Plate (Corning). The growth of blast
colonies was observed after 3 days. For further studies, the
BCs were hand-picked into Stemline II medium and dis-
persed mechanically to single cell suspension.
Hematopoietic differentiation of blast cells
The blast cells were resuspended in Methocult SF H4436
media supplemented with 0.5% of EX-CYTE (Millipore)
and plated onto untreated 12-well tissue culture plate
(Becton Dickinson). After 15 days, the morphology of the
colonies was assessed under inverted microscope Olym-
pus with phase-contrast, the pictures were taken with
Canon Digital Rebel XTi camera and the number of colo-
nies of different type was subsequently counted. The sin-
gle colony-forming units (CFUs) were hand-picked and
assessed either by RT-PCR or Wright-Giemsa staining
(Camco Quik Stain, Fischer, US).
Endothelial differentiation of blast cells
For endothelial differentiation, blast cells have been resus-
pended in EGM-2 complete media (Cambrex) and incu-
bated in fibronectin coated plates (Becton Dickinson) for
5 days. To prove that fibronectin-adhering cells are of
endothelial lineage, the Dil-Ac-LDL uptake assay was per-
formed. The cells were incubated with 10 ug/ml Dil-Ac-
LDL (R&D System) for 4 h, dissociated with Trypsin-EDTA
and spun onto glass slides. After fixation with 4% parafor-
maldehyde (Fischer) in PBS for 5 min., the cells were
counterstained with Hoechst 33342 (Invitrogen) and vis-
ualized under fluorescent microscope. Next, the capillary
formation assay was performed. Endothelial cells had
been resuspended in EGM-2 complete media and added
onto the surface of solidified Matrigel (BD Biosciences).
After 24 h of culture, the capillary formation was visual-
ized under the inverted Olympus microscope with phase
contrast, and pictures were taken using Canon Digital
Rebel XTi camera.
RT-PCR
RNA was isolated using RNeasy Mini Kit (QIAGEN) and
cDNA synthesis was performed with SuperScript® First-
Strand Synthesis System (Invitrogen) using the oligo(dT)
method according to manufacturers' protocols. In sam-
ples from single-colonies, cDNA was prepared using
CellsDirect cDNA Synthesis Kit (Invitrogen). To perform
semi-quantitative analysis, 5 ug of RNA from each sample
were used, the β-actin bands were used as internal loading
control and a minimum number of cycles were performed
to maintain the linearity of reaction. The sequences and
annealing temperatures for primers resulted from exten-
sive literature search and are listed in Table 1. PCR reac-
Table 1: The sequences of primers, product length and annealing temperatures used in RT-PCR reactions
Gene Forward primer Reverse primer Size (bp) Annealing temperature
β-Actin TTTGAATGATGAGCCTTCGTCCCC GGTCTCAAGTCAGTGTACAGGTAAGC 129 59
T TGTCCCAGGTGGCTTACAGATGAA GGTGTGCCAAAGTTGCCAATACAC 144 59
FOXA2 CCATTGCTGTTGTTGCAGGGAAGT CACCGTGTCAAGATTGGGAATGCT 196 59
NeuroD CCCATGGTGGGTTGTCATATATTCATGT CCAGCATCACATCTCAAACAGCAC 196 59
KDR CCTCTACTCCAGTAAACCTGATTGGG TGTTCCCAGCATTTCACACTATGG 219 59
CD34 AAATCCTCTTCCTCTGAGGCTGGA AAGAGGCAGCTGGTGATAAGGGTT 216 59
CD31 ATCATTTCTAGCGCATGGCCTGGT ATTTGTGGAGGGCGAGGTCATAGA 159 59
SCL AAGGGCACAGCATCTGTAGTCA AAGTCTTCAGCAGAGGGTCACGTA 104 59
PTCH CGCTGTCTTCCTTCTGAACC ATCAGCACTCCCAGCAGAGT 282 60
GLI1 CTCTGAGACGCCATGTTCAA ATCCGACAGAGGTGAGATGG 282 60
ε-globin CACTAGCCTGTGGAGCAAGATGAA AATCACCATCACGTTACCCAGGAG 304 59
γ-globin CGCTTCTGGAACGTCTGAGGTTAT CCAGGAGCTTGAAGTTCTCAGGAT 370 59
β-globin TGTCCACTCCTGATGCTGTTATGG AGCTTAGTGATACTTGTGGGCCAG 302 59Journal of Translational Medicine 2009, 7:27 http://www.translational-medicine.com/content/7/1/27
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tion was performed using Taq PCR Core Kit (QIAGEN) in
DNA Thermal Cycler 480 (PERKIN ELMER CETUS) and
the product was visualized in 2% agarose gel. (Table 1)
Immunostaining
For FACS analysis, blast cells were isolated, washed and
stained with appropriate monoclonal antibodies for 20
minutes at 4°C. The antibodies included: CD45-PerCp,
CD34-FITC, CD31-PE (from Becton Dickinson), CD146-
AF647, CD144(VE-cadherin)-PE, Flt-1-PE (from R&D Sys-
tems), CD33-PerCp (eBioscience). The cells were acquired
using BD FACSCalibur (Becton Dickinson) and analyzed
with FlowJo software (Tree Star).
Immunofluorescence microscopy
Carefully cleaned coverslips were incubated in poly-L-
lysine (Sigma) and dried for 24 hours. H9 cells, EB (day
3) cells and BC (day 6) cells were harvested, washed in
PBS, and were allowed to settle on the coated coverslips
for 30 min at 37°C. The cells were then fixed in 1% para-
formaldehyde for 30 min, washed with PBS, and the cov-
erslips were blocked with 1% BSA for 60 min. Staining for
HLA-A2 was performed with the FITC-conjugated anti-
body BB7.2 (BD Pharmingen) together with DAPI
(Promega) for 2 hours at room T°. The coverslips were
then washed with PBS and mounted with ProLong Gold
mounting medium (Invitrogen) on pre-cleaned micro-
scope slides. The slides were then dried overnight at room
T° in dark and observed under a Nikon fluorescent micro-
scope.
Results
Tracking the development of hES cell-derived 
hemangioblast
Based on current literature, hemangioblast represents a
transient cell stage during human development, and a
number of genes have been identified as indispensable for
hematopoiesis and/or blood vessel formation. We
hypothesized that hemangioblast arises early during
embryoid body formation and further undergoes differen-
tiation to more mature hematopoietic and endothelial
progenitors. We also hypothesized that the blast stage is
clearly associated with the emergence of expression of
hematopoietic and endothelial genes.
In order to find the exact time point when blast colony-
forming cells (BL-CFCs) arise in the EB system, we started
a series of BL-CFC cultures on days 0 to 6 of EB differenti-
ation in vitro. In our hands, while only single blast colo-
nies (BCs) were derived from day 2 EBs, there was a
striking burst of BCs on day 3 followed by rapid decline in
numbers (Figure 1A). On day 3, about 125 ± 35 out of
2400 EB cells formed BCs.
In order to define the correlation of hemangioblast forma-
tion with kinetics of gene expression, a semi-quantitative
RT-PCR analysis was performed using RNA samples iso-
lated from EBs at consecutive days of differentiation (Fig-
ure 1B). For analysis, we chose genes representing three
germ layers (T-mesoderm, FOXA2- endoderm, NEURO D-
ectoderm) and genes previously suggested to be closely
related to hemangioblast (KDR, SCL, CD34, CD31).
Moreover, we investigated expression of genes being a
marker of hedgehog pathway activation (PTCH1, GLI1),
as this pathway is implicated in early development of
both hematopoiesis and vasculogenesis [19]. We
observed that while T expression rapidly increased on day
1 of EB differentiation, it was gradually decreasing after
day 1. On the other hand, the expression of FOXA2 was
constantly increasing until day 4. In our culture condi-
tions, we did not observe any significant expression of
NEURO D; on day 3 of EB differentiation, we observed a
significant increase in expression of KDR, SCL, CD34,
CD31, PTCH1 and GLI1 genes. This was correlated with
the appearance of highest number of BCs (Figure 1B).
BCs had a characteristic grape-like appearance and con-
sisted of 30–50 loosely associated cells on day 6 (Figure
1C). These cells had homogenous morphology in Wright-
Giemsa stain with big nucleus containing disorganized
chromatin and narrow rim of cytoplasm filled with large-
size granules (Figure 1D). However, as shown by FACS
staining, they were quite heterogenous and to different
extent expressed markers of both hematopoietic (CD34+,
CD31+, CD45+) and endothelial cells (CD31+, CD34+,
VE-cadherin+, Flt-1+, CD146+). At least a proportion of
them were already committed to either endothelial
(CD146+) or hematopoietic (CD45+) lineage (Figure 1E).
Hematopoietic potential of blast cells
The colony forming unit (CFU) assay is traditionally used
to identify hematopoietic potential of certain cell popula-
tions. Characteristic morphology of derived colonies
allows estimation of the type, number and differentiation
stage of progenitor cells. Based on described phenotypes,
we hypothesized that we can use CFU assay to characterize
hematopoietic differentiation of EB-derived blast cells. In
order to prove that, day 6 blast cells have been plated in
Methocult H4436 medium. The morphology and number
of colonies was estimated on day 15 after initiation of cul-
ture. In this assay, we obtained growth of three distinctive
types of colonies (Figure 2A, B, C). The colony visualized
on Figure 2A was solely composed of nucleated red blood
cells and based on traditional nomenclature and colony
appearance; it was called BFU-E. The colony shown in Fig-
ure 2B contained both nucleated erythrocytes and cells
with macrophage morphology and was called CFU-EM.
The third type of colonies was composed of macrophages
only and therefore was called CFU-M (Figure 2C). FigureJournal of Translational Medicine 2009, 7:27 http://www.translational-medicine.com/content/7/1/27
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2D, E, F represent nucleated pre-erythrocytes (Figure 2D,
E) and macrophages (Figure 2F). The majority (63.4 ±
0.8%) of colonies were CFU-M, while BFU-E and CFU-EM
colonies existed at similar proportions (adequately 19.5 ±
3.5% and 17.1 ± 2.7%) (Figure 2G). As we wanted to con-
firm if the observed erythropoiesis was of fetal or adult
type, we performed RT-PCR analysis of globin genes from
single colonies; both blast cells from single BCs and BFU-
E colonies expressed only embryonic (ε) and fetal (γ)
globin genes and not the adult-type β-globin (Figure 2H).
Kinetics of hemangioblast formation in EB culture and characterization of blast cells Figure 1
Kinetics of hemangioblast formation in EB culture and characterization of blast cells. A) Kinetics of blast colony 
(BCs) formation from cells derived from EBs on consecutive days of development. EBs were dispersed to a single-cell suspen-
sion and specific number of live cells was seeded in a semisolid medium. Colonies were counted on day 6 of BC culture. Exper-
iment was performed in quadruplicates, and bars represent standard deviation (SD) from the mean. B) Dynamics of 
hemangioblast-related gene expression in EB differentiation system. Semi-quantitative RT-PCR was performed from RNA sam-
ples isolated from EBs picked on consecutive days of development. Input of RNA was normalized according to β-actin gene 
expression and minimal number of cycles was performed to achieve linearity of reaction. C) Blast colony on day 6 of culture 
(phase contrast, 100×). D) Blast cells on day 6 of blast culture (Wright-Giemsa stain, 200× light microscopy). E) FACS analysis 
of day 6 blast cells.
 Journal of Translational Medicine 2009, 7:27 http://www.translational-medicine.com/content/7/1/27
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Endothelial potential of blast cells
Based on the definition of hemangioblast, blast cells are
the cells which can differentiate not only to hematopoi-
etic progenitors, but also to functional endothelial cells,
which are able to create vascular structures and pick up
Dil-Ac-LDL. Therefore, we hypothesized that blast cells
can be successfully differentiated to cells with properties
of endothelium. In order to prove that, day 6 blast cells
have been cultured for 4 days in endothelial cell medium
on fibronectin-coated surface. The endothelial potential
of differentiated cells which adhered to this surface was
further assessed. After re-plating into Matrigel-containing
wells, they spontaneously formed vascular-like structures
after 24 hours of culture (Figure 3A). Moreover, they had
Hematopoietic differentiation of blast cells Figure 2
Hematopoietic differentiation of blast cells. Figures A-F show different types of hematopoietic colonies and cells derived 
from blast cells. A) burst forming unit-erythrocyte (BFU-E); B) colony forming unit- erythrocyte/macrophage (CFU-EM); C) 
colony forming unit-granulocyte/macrophage (CFU-GM) (40×, phase contrast); D) nucleated primitive erythrocytes from BFU-
E; E) erythrocytes and macrophage derived from CFU-EM; F) macrophage derived from CFU-M (original pictures 200×). G) 
proportions of CFU colonies derived from blast cells. Bars represent standard deviations from the mean. H) analysis of globin 
genes expression in blast colony (BC), BFU-E and in undifferentiated hES cells (negative control).
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the ability to take up Dil-Ac-LDL, which is a unique prop-
erty of endothelial cells (Figure 3B). We concluded that
blast cells have the ability to form endothelial progenitors
as well as form vascular structures in vitro.
HLA expression of hES cells, EB cells and blast-like 
colonies (BLCs)
To analyze expression of MHC-I proteins on the surface of
human ES cells and their derivatives, we used monoclonal
antibody BB7.2 directed against a subunit of the human
leukocyte antigen-A2 (HLA-A2). Staining with this anti-
body revealed very low levels of HLA-A2 expression in the
H9 human ES cell line. We also examined whether differ-
entiation process of human ES cells would cause HLA-A2
upregulation. Differentiation of human ES cells into EBs
resulted in a mild elevation of HLA-A2 protein expression
(2- to 4-fold increase). Expression level of HLA-A2 pro-
teins on the surface of combined blast colonies cells, as
well as on cells derived from individual blast colonies was
only moderately elevated. It is important to note, how-
ever, that the expression levels of HLA-A2 proteins on the
surface of human ES-derived blast cells were still lower
than those observed in the control human somatic cells.
This lower level of HLA-A2 expression most likely reflects
the relatively early nature of the blast cells derived from
human ES cells (Figure 4), although they did explain
potential to differentiate into endothelial and hematopoi-
etic progenitors.
Discussion
Future clinical applications of human ES cells and their
progenitors will require that they do not express or express
only low levels of HLA antigens, which can be tolerated by
the host immune system. In this work, for the first time,
we describe low expression of HLA antigens in human ES,
EB, and blast cells with dual hematopoietic and endothe-
lial potential, which may have future clinical applications.
Although some published data on the existence of murine
and adult human hemangioblast exist [6], only recently
two different research groups have used the hES/EB cell
differentiation system in vitro to investigate human
Characterization of blast cell-derived endothelial cells Figure 3
Characterization of blast cell-derived endothelial 
cells. A) vascular structures in Matrigel formed by endothe-
lial cells after 24 h of culture (400×, phase contrast) B) Dil-
Ac-LDL uptake by endothelial cells: red – Dil-Ac-LDL; blue- 
Hoechst (nuclei) (200×, immunofluorescence).
 
Relative HLA-A2 expression Figure 4
Relative HLA-A2 expression. Positive control cells K562-A2, negative control cells EL-4, undifferentiated ES cell line H9 
(ES), EB cells (EB), blast colonies (BC), endothelial differentiated (EC) and hematopoietic differentiated (HC) cells were stained 
with the FITC-labeled anti-HLA-A2 antibody B B7.2 and relative immunefluorescence was quantified and expressed as a per-
centage of positive control.
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embryonic hemangioblast. Both Kennedy et al. [12] and
Lu et al. [13] used ES/EB system to differentiate very early
dual hematopoietic/endothelial precursors which were
capable of formation of blast colonies (BCs). Although
they applied different culture conditions and the pheno-
type of obtained blast cells significantly differed, in both
cases, these cells could differentiate to both blood and
endothelial progenitors.
Similar to the above publications, we performed hES cell
differentiation in EB system and obtained blast colonies
which were further shown to be bipotential. As the main
scope of our studies was the evaluation of clinical applica-
tion of blast cells, we adopted our culture conditions from
Lu et al. [13] and studied HLA expression in these cul-
tures. This methodology seems to be superior in order to
not only investigate the existence of blast cells, but also to
upscale its production. In the EB system, the early devel-
opment of mesoderm and hemangioblast was stimulated
with sequentially used growth factors: VEGF and BMP-4
in order to enhance mesodermal differentiation, and
BMP-4, VEGF, Tpo, SCF and Flt3L to stimulate formation
of early hematopoietic/endothelial precursors. We modi-
fied the ES-derived blast cell culture conditions using
commercially available Methocult SF H4436 semisolid
medium supplemented with BMP-4, VEGF, Tpo and
Flt3L.
The blast colonies obtained by us had similar morphology
as previously described, but they were composed of lower
number of cells. Most likely this resulted from differences
between hES cell lines used. Both Kennedy et al and Lu et
al presented data based on H1 hES cells while we were
using H9 cell line. As in the above papers, blast cells
expressed embryonic and fetal globin genes, so at least
some of them already differentiated to the erythroid line-
age. Contrary to Lu et al., some of our ES-derived blast
cells expressed CD31, CD34 and VE-cadherin, the mole-
cules thought to be closely associated with the phenotype
of hemangioblast [12]. However, some of the blast cells in
culture were already terminally differentiated and were
shown to express either exclusively hematopoietic marker
CD45 or endothelial antigen CD146.
Despite this fact, the blast cells produced in our condi-
tions could be successfully differentiated to either func-
tional endothelial cells or blood cells. We observed
growth of colony forming units composed of either prim-
itive nucleated erythrocytes, macrophages or both these
lineages. Therefore, our culture system most likely paral-
lels very early yolk sac hematopoiesis where only these
cell populations exist. The similar type CFUs were
obtained by Kennedy et al. Contrary to Lu et al., we did
not obtain growth of multilineage colonies containing
also megakaryocytes and granulocytes, which may be due
to the modification of culture conditions described in
methods and materials.
In both reports, as well as in our studies, it was shown that
the majority of colonies, but not necessarily single cells,
are bipotential. This suggests that hemangioblast exists at
the EB stage and gives rise to bipotential cell clone. But,
are the single blast cells also bipotential? Lu et al. reported
that cells from primary blast colonies can form secondary
colonies and a proportion of them maintain bipotential-
ity. This means that at least some of the blast cells have
properties of hemangioblast. We also investigated this
issue, but the yield of secondary colonies was very low and
the majority of them formed BFU-E colonies rather than
blast colonies. Therefore, based on our observations, it is
most likely that the majority of blast cells obtained at day
6 are already committed precursors of blood cells or
endothelium. In this situation, the real hemangioblast
seems to occur mainly at EB stage and is transient.
In order to prove how long cells persist in a hemangiob-
last or hemato-endothelial precursor stage, as well as how
to optimize the yield of EB-derived blast cells, we per-
formed an experiment with sequential formation of blast
cells from EBs from day 0 to 6. Based on our data, it is
clear that blast colony-forming cells (BL-CFCs) – or dual
hemato-endothelial precursors arise early in EB develop-
ment and are called hemangioblasts (day 3). Moreover,
we performed semi-quantitative RT-PCR analysis of gene
expression in developing EBs, confirming that the differ-
entiation of BL-CFCs occurs just after differentiation of
mesoderm layer and was suppressed by a subsequent
development of endoderm. We also observed that the
expression of a number of hemangioblast-related genes
(CD34, CD31, KDR) peaks exactly at the time point when
BL-CFCs aroused. Therefore they can be used in quantita-
tive analysis of hemangioblast differentiation in EB cul-
ture (and in improved culture conditions) to obtain a
higher yield of cells. The increased expression of genes of
Hedgehog pathway signaling on day 3 suggests that their
action may be related to the differentiation of early
hemangioblasts. Based on the literature, Hedgehog signal-
ing is important for embryonic hematopoiesis and vascu-
logenesis, and it was suggested that it enhances paracrine
BMP-4 signaling, leading to the development of blast-like
cells [19,20].
Blast cells differentiating from hemangioblasts or
hemato-endothelial precursors appear at a very early stage
of ES differentiation, and it is unclear from previous stud-
ies whether it expresses HLA molecules. In this work, we,
for the first time, demonstrated that the blast cells express
HLA molecules at an elevated level compared with their
precursors: ES and EB cells. Other studies have also dem-
onstrated low levels of expression of MHC class I mole-Journal of Translational Medicine 2009, 7:27 http://www.translational-medicine.com/content/7/1/27
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cules in human undifferentiated ES cells [21-24], while
the levels of MHC class I molecules on human ES cells
upon differentiation were reported to be slightly down-
regulated [21] or moderately upregulated [22]. These
observations suggest that ES cell-derived therapeutics will
most likely express MHC class I, and that they may be rec-
ognized by T cells and rejected upon transplantation.
However, this issue still needs further detailed studies.
Based on our data, although the blast cells can be charac-
terized by mildly increased HLA expression compared to
negative controls, e.g. ES and EB cells, it is still much lower
than in differentiated endothelial and hematopoietic
cells. Moreover, several published studies suggest
immune- privileged properties of ES-derived cell products
[23,25-28]. Human ES cells do not express co-stimulatory
molecules and many other immune-related genes [24,29].
Moreover, the undifferentiated and differentiated ES cells
were shown to be protected against T cell-mediated
immune responses due to a high-level expression of the
granzyme B inhibitor [28]. In addition, human and
murine ES cells are capable of actively modulating
immune reactions as demonstrated by their ability to
inhibit third-party allogeneic dendritic cell-mediated T
cell proliferation [23], to abrogate ongoing alloresponses
in mixed lymphocyte reactions [26,30] and to completely
prevent T cell cytotoxicity against allogeneic ConA blasts
in vitro [31]. Although human ES cells express relatively
low levels of MHC-I, it was shown that they were also
insensitive to human natural killer (NK) cell-mediated
cytotoxicity [22]. The resistance of hematopoietic stem
cells to immune attack was shown in a previous study
[32]. Notably, embryonic tissues from early gestational
stages were also known to be less immunogenic than their
adult counterparts [33]. In conclusion, we suggest that the
ES cells and their early progenitors could evade immune
surveillance due to their low immunostimulatory poten-
tial, and thus have future clinical potential.
Conclusion
Based on current studies we conclude that hemangioblasts
transiently exist at early ES/EB stage and then differentiate
into blast cells. The bipotentiality of hemangioblast and
blast cells provides the opportunity to use them in future
cellular therapies of human disorders. Moreover, the blast
cells can possibly find their application in the future
regenerative medicine. They can successfully differentiate
into endothelial cells and form vascular structures; there-
fore, they can potentially be used in different disorders
where blood vessel structures are damaged physically or
by inflammation, or when organs need rapid additional
blood supply to maintain their functions (e.g. in case of
heart infarction). For the first time, we have demonstrated
low levels of HLA antigen expression in human blast cells,
which supports their future clinical applications.
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